Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

8.550 +0.510 (+6.34%)
Streaming Delayed Price Updated: 1:46 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. 
Via Investor's Business Daily
The Analyst Landscape: 4 Takes On Amicus Therapeutics
 
Via Benzinga
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease - 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Time to buy these 3 healthcare companies that raised revenue guidance?
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
Via MarketBeat
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
From Amicus Therapeutics, Inc.
Via GlobeNewswire
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps
These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on. 
Via InvestorPlace
Topics Bankruptcy
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease
The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease. 
Via Benzinga
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. 
Via Investor's Business Daily
Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating
On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier. 
Via Investor's Business Daily
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD) 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.